Aerovate Therapeutics Stock Forecast, Price & News

Aerovate Therapeutics (NASDAQ:AVTE) Frequently Asked Questions

Is Aerovate Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aerovate Therapeutics stock.
View analyst ratings for Aerovate Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Aerovate Therapeutics?

Wall Street analysts have given Aerovate Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerovate Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,110,000 shares, an increase of 30.7% from the September 15th total of 849,100 shares. Based on an average daily trading volume, of 115,400 shares, the days-to-cover ratio is currently 9.6 days. Approximately 6.5% of the company's stock are short sold.
View Aerovate Therapeutics' Short Interest.

When is Aerovate Therapeutics' next earnings date?

Aerovate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Aerovate Therapeutics.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings data on Sunday, August, 15th. The company reported ($23.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $23.64.
View Aerovate Therapeutics' earnings history.

What price target have analysts set for AVTE?

4 brokers have issued 12-month price targets for Aerovate Therapeutics' shares. Their forecasts range from $21.00 to $23.00. On average, they anticipate Aerovate Therapeutics' share price to reach $22.00 in the next year. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Aerovate Therapeutics or view top-rated stocks among Wall Street analysts.

Who are some of Aerovate Therapeutics' key competitors?

Some companies that are related to Aerovate Therapeutics include Supernus Pharmaceuticals (SUPN), Avid Bioservices (CDMO), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), MorphoSys (MOR), Kadmon (KDMN), NGM Biopharmaceuticals (NGM), Travere Therapeutics (TVTX), PureTech Health (PRTC), Bicycle Therapeutics (BCYC), Centessa Pharmaceuticals (CNTA), Protagonist Therapeutics (PTGX), Organogenesis (ORGO), Zealand Pharma A/S (ZEAL) and Enanta Pharmaceuticals (ENTA).
View all of AVTE's competitors.

When did Aerovate Therapeutics IPO?

(AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

What is Aerovate Therapeutics' stock symbol?

Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."

When does the company's lock-up period expire?

Aerovate Therapeutics' lock-up period expires on Monday, December 27th. Aerovate Therapeutics had issued 8,682,142 shares in its IPO on June 30th. The total size of the offering was $121,549,988 based on an initial share price of $14.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerovate Therapeutics' stock price today?

One share of AVTE stock can currently be purchased for approximately $16.89.

How much money does Aerovate Therapeutics make?

Aerovate Therapeutics has a market capitalization of $412.28 million.

How many employees does Aerovate Therapeutics have?

Aerovate Therapeutics employs 2,021 workers across the globe.

What is Aerovate Therapeutics' official website?

The official website for Aerovate Therapeutics is aerovatetx.com.

How can I contact Aerovate Therapeutics?

The company can be reached via phone at 617-443-2400 or via email at [email protected].